131 related articles for article (PubMed ID: 21902160)
1. Teriparatide (rh [1-34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening.
Oteo-Álvaro Á; Matas JA; Alonso-Farto JC
Orthopedics; 2011 Sep; 34(9):e574-7. PubMed ID: 21902160
[TBL] [Abstract][Full Text] [Related]
2. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
3. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
5. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Lems WF; Hamdy NA; Netelenbos JC
Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
[TBL] [Abstract][Full Text] [Related]
6. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
7. The influence of parathyroid hormone treatment on implant fixation.
Daugaard H
Dan Med Bull; 2011 Sep; 58(9):B4317. PubMed ID: 21893015
[TBL] [Abstract][Full Text] [Related]
8. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
9. Use of teriparatide in osteoporotic fracture patients.
Collinge C; Favela J
Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
[TBL] [Abstract][Full Text] [Related]
10. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
11. Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures.
Huang TW; Huang KC; Lin SJ; Chuang PY; Shih HN; Lee MS; Hsu RW; Shen WJ
BMC Musculoskelet Disord; 2016 Jul; 17():300. PubMed ID: 27435235
[TBL] [Abstract][Full Text] [Related]
12. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
Stroup JS; Rivers SM; Abu-Baker AM; Kane MP
Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760
[TBL] [Abstract][Full Text] [Related]
13. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL
J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
Skiba K; Adamczak M; Wiecek A
Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
16. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
17. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
18. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
19. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
[TBL] [Abstract][Full Text] [Related]
20. Surgical approach to fragility fractures: problems and perspectives.
Tarantino U; Cannata G; Cerocchi I; Lecce D; Iundusi R; Celi M
Aging Clin Exp Res; 2007 Aug; 19(4 Suppl):12-21. PubMed ID: 18182887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
